tbuckley/cabot-search huggingface dataset:
Cell-specific epigenome-wide DNA methylation profile in long-term cultured minor salivary gland epithelial cells from patients with Sjögren's syndrome
Authors: Amandine Charras, Orsia D Konsta, Christelle Le Dantec, Cristina Bagacean, Efstathia K Kapsogeorgou, Athanasios G Tzioufas, Jacques-Olivier Pers, Anne Bordron, Yves Renaudineau
Journal: Annals of the Rheumatic Diseases (2017)

The aetiology of primary Sjögren's syndrome (pSS), also referred to as autoimmune epithelitis, is incompletely understood but includes an epigenetic contribution. Accordingly, the aim of this study was to investigate DNA methylation in salivary gland epithelial cells (SGEC), and to compare results with those publicly available from pSS B and T cells.Long-term cultured SGEC were selected to conduct an epigenome-wide association study (EWAS) in patients with pSS with comparison to controls using the HumanMethylation 450 K array from Illumina.The analysis of differentially methylated CpG (DMC) uncovered 4662 positions corresponding to 2560 genes, and 575 genes with two or more DMC sites (DMCs), in SGEC as compared with controls. Further analysis highlighted an important proportion of interferon-regulated genes (61%), the calcium pathway (hypomethylated) and the Wnt pathway (hypermethylated). When comparing SGEC with pSS T and/or B cell results, an important overlap was observed with respect to differentially methylated genes (38.8%) and pSS risk factors (71.4%), although such assertion was not true when comparing DMCs.This study conducted in SGEC emphasises the role of DNA methylation in pSS pathogenesis and supports the necessity to conduct pure cell analysis for future EWAS studies when analysing salivary glands from patients with pSS.
Unrelated Stem Cell Transplantation (SCT) after a Reduced Intensity Conditioning (RIC) Regimen Containing 25 mg/kg Thymoglobulin (THY): Controllable Graft Versus Host Disease (GVHD) Contributes to Survival Benefit.
Authors: J.F. Lacerda, C. Martins, F. Lourenco, J.A. Carmo, C. Juncal, J.J.G. Oliveira, J.M.F. Lacerda
Journal: Blood (2006)
ClinGen Pathogenicity Calculator: a configurable system for assessing pathogenicity of genetic variants
Authors: Ronak Y. Patel, Neethu Shah, Andrew R. Jackson, Rajarshi Ghosh, Piotr Pawliczek, Sameer Paithankar, Aaron Baker, Kevin Riehle, Hailin Chen, Sofia Milosavljevic, Chris Bizon, Shawn Rynearson, Tristan Nelson, Gail P. Jarvik, Heidi L. Rehm, Steven M. Harrison, Danielle Azzariti, Bradford Powell, Larry Babb, Sharon E. Plon, Aleksandar Milosavljevic
Journal: Genome Medicine (2017)

The success of the clinical use of sequencing based tests (from single gene to genomes) depends on the accuracy and consistency of variant interpretation. Aiming to improve the interpretation process through practice guidelines, the American College of Medical Genetics and Genomics (ACMG) and the Association for Molecular Pathology (AMP) have published standards and guidelines for the interpretation of sequence variants. However, manual application of the guidelines is tedious and prone to human error. Web-based tools and software systems may not only address this problem but also document reasoning and supporting evidence, thus enabling transparency of evidence-based reasoning and resolution of discordant interpretations. In this report, we describe the design, implementation, and initial testing of the Clinical Genome Resource (ClinGen) Pathogenicity Calculator, a configurable system and web service for the assessment of pathogenicity of Mendelian germline sequence variants. The system allows users to enter the applicable ACMG/AMP-style evidence tags for a specific allele with links to supporting data for each tag and generate guideline-based pathogenicity assessment for the allele. Through automation and comprehensive documentation of evidence codes, the system facilitates more accurate application of the ACMG/AMP guidelines, improves standardization in variant classification, and facilitates collaborative resolution of discordances. The rules of reasoning are configurable with gene-specific or disease-specific guideline variations (e.g. cardiomyopathy-specific frequency thresholds and functional assays). The software is modular, equipped with robust application program interfaces (APIs), and available under a free open source license and as a cloud-hosted web service, thus facilitating both stand-alone use and integration with existing variant curation and interpretation systems. The Pathogenicity Calculator is accessible at http://calculator.clinicalgenome.org . By enabling evidence-based reasoning about the pathogenicity of genetic variants and by documenting supporting evidence, the Calculator contributes toward the creation of a knowledge commons and more accurate interpretation of sequence variants in research and clinical care.
New diagnosis of polycystic ovary syndrome
Authors: Isabel McLuskie, Aisha Newth
Journal: BMJ (2017)

#### What you need to know

A 27 year old woman with a recent diagnosis of polycystic ovary syndrome comes to see you. She wants to know more about the condition and the consequences for her health (box 1).

#### Box 1: Background facts

Polycystic ovary syndrome affects 6%-7% of women.1

Women may experience

The relation between polycystic ovary syndrome and obesity is poorly understood. Polycystic ovary syndrome is not caused by, and does not cause, obesity. However, obesity is associated with an increase in secondary complications in women with polycystic ovary syndrome, such as:



Fig 1  A diagram showing the interaction between the hormonal profile and metabolic features of polycystic ovary syndrome



Find out what the patient understands about her condition and explore how it is affecting her. Consider covering:

Irregular periods Prolonged oligomenorrhoea or amenorrhoea can increase the risk of endometrial hyperplasia and cancer. …
Tiotropium in paediatric asthma
Authors: Jonathan Grigg
Journal: European Respiratory Journal (2017)

The emerging evidence that there are many types of asthma that may respond differently to treatment suggests a need for novel inhaled therapies beyond the current armamentarium of short-acting β2-agonists, long-acting β2-agonists (LABA) and inhaled corticosteroids (ICS). Recent phase III trials suggest that tiotropium, a long-acting muscarinic antagonist, is a promising treatment for adult asthma. In this patient population, two recent Cochrane reviews have evaluated: 1) adding tiotropium to LABA/ICS combinations in patients whose asthma is not well controlled by LABA/ICS alone; and 2) adding tiotropium to ICS compared with adding a LABA to ICS. No significant benefit of inhaled tiotropium was found in a trial in children and young people with severe asthma <http://ow.ly/jmK1306ck1N>
Palifermin Does Not Influence the Incidence and Severity of GvHD Nor Long-Term Survival of Patients with Hematological Diseases Undergoing HSCT
Authors: Barbara Nasilowska-Adamska, Agnieszka Tomaszewska, Richard M. Szydlo, Piotr Rzepecki, Anna Czyz, Joanna Manko, Miroslaw Markiewicz, Tigran Torosian, Maria Bieniaszewska, Beata Piatkowska-Jakubas, Agnieszka Wierzbowska, Dorota Duda, Andrzej Szczepinski, Andrzej Lange, Tadeusz Robak, Aleksander Skotnicki, Andrzej Hellman, Wieslaw W. Jedrzejczak, Jerzy Holowiecki, Anna Dmoszynska, Mieczyslaw Komarnicki, Krzysztof Warzocha, Bozena Marianska
Journal: Blood (2008)
Polymorphisms in Coagulant and Inflammatory Genes Modify the Phenotype of Severe Hemophilia A and B.
Authors: G. Jayandharan, Mercy Devadharshini, Auro Viswabandya, Sukesh C. Nair, R.V. Shaji, Vikram Mathews, Mammen Chandy, Alok Srivastava
Journal: Blood (2006)
Direct Confirmation of Quiescent Property of AML Stem Cells by Showing Markedly Decreased Plating Efficiency in Single Leukemic Stem Cell Culture
Authors: Myung-Geun Shin, Hye-Ran Kim, Chang-Soo Kim, Hyeoung-Joon Kim, Hoon Kook, Seung- Jung Kee, Soo-Hyun Kim, Jong-Hee Shin, Soon-Pal Suh, Dong-Wook Ryang
Journal: Blood (2008)
The Elusive Progenitor Cell in Cardiac Regeneration
Authors: Chen-Leng Cai, Jeffery D. Molkentin
Journal: Circulation Research (2017)

The adult human heart is unable to regenerate after various forms of injury, suggesting that this organ lacks a biologically meaningful endogenous stem cell pool. However, injecting the infarcted area of the adult mammalian heart with exogenously prepared progenitor cells of various types has been reported to create new myocardium by the direct conversion of these progenitor cells into cardiomyocytes. These reports remain controversial because follow-up studies from independent laboratories failed to observe such an effect. Also, the exact nature of various putative myocyte-producing progenitor cells remains elusive and undefined across laboratories. By comparison, the field has gradually worked toward a consensus viewpoint that proposes that the adult mammalian myocardium can undergo a low level of new cardiomyocyte renewal of ≈1% per year, which is primarily because of proliferation of existing cardiomyocytes but not from the differentiation of putative progenitor cells. This review will weigh the emerging evidence, suggesting that the adult mammalian heart lacks a definable myocyte-generating progenitor cell of biological significance.
Obstructive sleep apnoea as a cause of nocturnal nondipping blood pressure: recent evidence regarding clinical importance and underlying mechanisms
Authors: Sophie J. Crinion, Silke Ryan, Walter T. McNicholas
Journal: European Respiratory Journal (2017)

Obstructive sleep apnoea (OSA) is highly prevalent, with recent general population studies indicating that up to 50% of males and 23% of females have moderate or severe sleep disordered breathing (SDB) based on an apnoea–hypopnoea index (AHI) of >15 events·h–1 [1, 2]. OSA is recognised as an independent risk factor for systemic hypertension [3] and a nondipping nocturnal blood pressure profile is particularly likely in patients with OSA [4], even in the absence of significant hypertension. Furthermore, hypertension is increasingly recognised as an important predictor of prevalent OSA and appears to be more predictive than excessive day-time sleepiness in some settings [5]. However, recent evidence also indicates that only moderate–severe OSA (AHI >20 events·h–1) constitutes a significant independent risk for hypertension [2] and cluster analysis of sleep clinic populations indicates that particular population subtypes are especially associated with hypertension [6]. OSA is strongly associated with nondipping nocturnal blood pressure, which may help predict clinical significance <http://ow.ly/HToK305OnCV>
Myeloid-Derived Suppressor Cells (MDSC) Are Effectors of Bone Marrow Suppression in Lower Risk Myelodysplastic Syndromes (MDS).
Authors: Sheng Wei, Xianghong Chen, Kathy Rocha, Dahui Qi, Jianguo Tao, Nicole Gjertsen, Junmin Zhou, Jinhong Liu, Dmitry Gabrilovich, P.K. Epling-Burnette, Julie Y Djeu, Alan F. List
Journal: Blood (2009)
High-dose chemotherapy and stem cell support in the management of metastatic germ cell cancer: A quantitative review
Authors: H. S. Bozcuk, M. Ozdogan, H. S. Coskun, H. Mutlu, A. Kargi, M. Uysal, B. Savas
Journal: Journal of Clinical Oncology (2009)

e16094 Background: To analyze the independent associates of outcome in metastatic germ cell cancer (MGCC) patients treated with high dose chemotherapy (HDC) and stem cell rescue. Methods: Thirty-two published patient cohorts with MGCC (encompassing 2176 patients; 510 patients treated upfront and 1666 at relapse) were identified from PUBMED and Cochrane Registry of Clinical Trials. Weighed Regression Analyses of these trials were conducted to define prognosticators. Results: Correlate of overall survival (OAS) and survival with no evidence of disease (NED) in upfront HDC trials was number of chemotherapeutics in HDC (OAS with 2 agents: 60% vs. 3 or more agents: 72%, p = 0.047, survival with NED with 2 agents: 47% vs. 3 or more agents: 64%, p = 0.009). In trials of HDC at relapse, independent associates of OAS with multivariate analysis were line of chemotherapy index, an indicator of line of chemotherapy utilization (p = 0.004), and median age (≤30: 42%, &gt;30: 49%, p = 0.023), whereas independent correlates of better survival with NED were again number of chemotherapeutics in HDC (2 agents: 54% vs. 3 or more agents: 33%, p = 0.001), and seminoma fraction (seminoma fraction ≤9%: 28% vs. seminoma fraction &gt;9%: 49%, p &lt; 0.001 ). Toxic mortality of HDC regimens employed in these trials ranged between 0% and 17%. Conclusions: HDC can cure patients with MGCC both as initial or salvage therapies. However, this study shows that type and setting of HDC, as well as patient age, and seminoma fraction all appear to be linked with benefit from HDC in MGCC. Future trials should continue to address the usage of tandem HDC cycles with multiagent protocols in high risk patients with MGCC. No significant financial relationships to disclose.
Mechanisms and New Strategies for Primary Sjögren's Syndrome
Authors: Clio P. Mavragani
Journal: Annual Review of Medicine (2017)

Primary Sjögren's syndrome (SS) is a common chronic autoimmune disease characterized by lymphocytic infiltration of exocrine glands, mainly salivary and lacrimal, resulting in oral and ocular dryness, although virtually any organ system can be affected. SS-related systemic manifestations are classified as either related to the presence of periepithelial infiltrates in exocrine and parenchymal organs or resulting from immunocomplex deposition due to B cell hyperactivity with increased risk for B cell lymphoma development. Activation of both innate and adaptive immune pathways contributes to disease pathogenesis, with prominent interferon (IFN) signatures identified in both peripheral blood and affected salivary gland tissues. Recently, LINE-1 genomic repeat elements have been proposed as potential triggers of type I IFN pathway activation in SS through activation of Toll-like receptor–dependent and –independent pathways. In view of the increasingly appreciated variability of SS, elucidation of distinct operating pathways in relation to diverse clinical phenotypes and selection of the optimal therapeutic intervention remain major challenges. Inhibition of cathepsin S molecules, blockade of costimulation through administration of abatacept and inhibitors of B7-related molecules and CD40, blockade of B cell function and B cell survival factors, and disruption of the formation of ectopic germinal centers are considered the main therapeutic targets. Well-controlled multicenter clinical trials are ongoing and data are awaited.
Fcgammariib Expression As a Prognostic Marker in Chronic Lymphocytic Leukemia
Authors: Rosa Bosch, Gerardo Ferrer, Eva Puy Vicente, Alba Mora, Rajendra N. Damle, Sergey Gorlatov, Kanti Rai, Emili Montserrat, Jorge Sierra, Nicholas Chiorazzi, Carol Moreno
Journal: Blood (2015)
Central Nervous System (CNS) Relapse in Adult Patients with Acute Lymphoblastic Leukemia (ALL): Frequency and Prognosis in 467 Patients without Cranial Irradiation for CNS Prophylaxis.
Authors: Juan-Manuel Sancho, Josep-Maria Ribera, Albert Oriol, Jesus-Maria Hernandez-Rivas, Concepcion Rivas, Concepcion Bethencourt, Javier Fernández-Calvo, Ricardo Parody, Guillermo Deben, Jose-Luis Bello, Josep-Maria Marti, Eugenia Abella, Eloy Del-Potro, Maria-Jose Terol, Evarist Feliu
Journal: Blood (2005)
Combined Inhibition of Wee1 and Poly(ADP Ribose) Polymerase1/2 Synergistically Inhibits Acute Myeloid Leukemia Cells By Enhancing DNA Damage and the Induction of Apoptosis
Authors: Jonathan C Snedeker, Tamara M Burleson, Raoul Tibes, Christopher C. Porter
Journal: Blood (2014)
Phenotypic and Genotypic Characteristics of Mastocytosis Differ According to the Age of Disease’s Onset.
Authors: Fanny Lanternier, Annick Cohen-Akenine, Fabienne Palmerini, Frederic Feger, Laurent Nasca, Stephane Barete, David Guez, Philippe Casassus, Christine Bodemer, Michel Arock, Patrice Dubreuil, Olivier Hermine, Olivier Lortholary
Journal: Blood (2005)
Use of Lenalidomide in DEL(5q) MDS. a National AIFA (Agenzia Italiana del Farmaco) Registry Study
Authors: Francesco Arcioni, Andrea Roncadori, Valeria Di Battista, Giuliana Alimena, Fabrizio Pane, Giuseppe Rossi, Francesco Buccisano, Anna D'Emilio, Nicola Di Renzo, Pietro Leoni, Giovanni Caocci, Alessandro Rambaldi, Paolo Avanzini, Giuseppe Visani, Sante Tura, Anna Covezzoli, Cristina Mecucci
Journal: Blood (2015)
FDG PET Functional Imaging in Multiple Myeloma - Clinically Important Caveats, Pitfalls, and Pearls.
Authors: Ronald Walker, L. Jones-Jackson, M. Miceli, Elias Anaissie, T. Alpe, R. Walker, Joshua Epstein, Guido Tricot, John Shaughnessy, Bart Barlogie
Journal: Blood (2004)
Commentary: It’s not all doom and gloom…but the crunch is coming
Authors: Nicholas Timmins
Journal: BMJ (2017)

Iacobucci’s summary of government funding and policy paints a picture of pretty unremitting gloom.1 There is in fact a brighter side to some of this—that is, how well the NHS has coped with the big financial squeeze of the past six years.

The service has in fact managed to do more, indeed much more. Activity, on almost every measure, is up.2 Not all of it is desirable activity. The rapid rise in attendances at emergency departments reflects, almost certainly, the …
Gates launches $1bn vaccine initiative to target emerging infectious diseases
Authors: Anne Gulland
Journal: BMJ (2017)

Philanthropist Bill Gates is spearheading a coalition of partners to head off the next global epidemic by focusing on the development of vaccines for three emerging infectious diseases.

The Coalition for Epidemic Preparedness Innovations, launched at the World Economic Forum in Davos, Switzerland, this week, has an initial investment of $460m (£373.5m; €431.5m) to target Middle East respiratory syndrome coronavirus (MERS-CoV), Lassa fever, and Nipah virus, which the coalition says have the potential to cause …
Neonatal Catecholaminergic Ventricular Tachycardia:A Case Report
Authors: Hisashi Sugiyama, Jun Yanai, Takayuki Komai, Tetsushi Tan, Sadayoshi Komori, Shinpei Nakazawa
Journal: Circulation (1999)

A case of neonatal catecholaminergic ventricular tachycardia is reported. Episodes of fetal tachycardia were detected in a female baby and just after birth, sustained monomorphic ventricular tachycardia of complete left bundle branch block pattern and inferior axis were recorded, suggesting a right ventricular outflow origin. Routine examination did not reveal overt heart disease. Ventricular tachycardia was induced by crying or sucking, elicited by isoproterenol infusion, and was suppressed by intravenous injection of ATP or propranolol. The baby's arrhythmia was controlled with oral propranolol. The ventricular tachycardia seemed to be caused by triggered activity. (Jpn Circ J 1999; 63: 727 - 728)
Platelet CD34 expression and α/δ-granule abnormalities in GFI1B- and RUNX1-related familial bleeding disorders
Authors: Anna E. Marneth, Waander L. van Heerde, Konnie M. Hebeda, Britta A. P. Laros-van Gorkom, Wideke Barteling, Brigith Willemsen, Aniek O. de Graaf, Annet Simons, Joop H. Jansen, Frank Preijers, Marjolijn C. Jongmans, Bert A. van der Reijden
Journal: Blood (2017)
High Expression of Lymphoid Enhancer-Binding Factor 1 (LEF1) Is a Novel, Favorable Prognostic Marker in Cytogenetically Normal AML and Is Associated with Upregulation of T-Lymphoid Lineage Markers in AML Blasts.
Authors: Klaus H. Metzeler, Bernhard Heilmeier, Konstantin Petropoulos, Maria C. Sauerland, Achim Heinecke, Wolfgang E Berdel, Thomas Buechner, Jan Braess, Karsten Spiekermann, Michaela Feuring-Buske, Wolfgang Hiddemann, Stefan K Bohlander, Christian Buske
Journal: Blood (2009)
Treatment with Fludarabine and Rituximab Produces Extended Overall Survival (OS) and Progression-Free Survival (PFS) in Chronic Lymphocytic Leukemia (CLL) without Increased Risk of Second Malignancy: Long-Term Follow up of CALGB Study 9712.
Authors: Jennifer A Woyach, Amy S Ruppert, Nyla A. Heerema, Bercedis Peterson, John G. Gribben, Vicki A. Morrison, Kanti R Rai, Richard A. Larson, John C. Byrd
Journal: Blood (2009)
Is Primary Biliary Cirrhosis a Rare Cause of Eosinophilia? A Case Report.
Authors: Niki E. Tsesmeli, Christos G. Savopoulos, Georgia D. Kaiafa, Apostolos I. Hatzitolios, Eleni E. Vretou, Athanasios Papadopoulos, Dimitrios P. Koliouskas
Journal: Blood (2005)
Decreased Expression of the Histone Methyltransferase SUV39H1 in AML Cells Reactivates Hypermethylated Tumor Suppressor p15INK4B in the Absence of Promoter Demethylation.
Authors: Ashakumary Lakshmikuttyamma, Stuart Scott, C. Ronald Geyer, John F. DeCoteau
Journal: Blood (2007)
CpG Methylation Signature Predicts Recurrence in Early-Stage Hepatocellular Carcinoma: Results From a Multicenter Study
Authors: Jiliang Qiu, Baogang Peng, Yunqiang Tang, Yeben Qian, Pi Guo, Mengfeng Li, Junhang Luo, Bin Chen, Hui Tang, Canliang Lu, Muyan Cai, Zunfu Ke, Wei He, Yun Zheng, Dan Xie, Binkui Li, Yunfei Yuan
Journal: Journal of Clinical Oncology (2017)

Purpose Early-stage hepatocellular carcinoma (E-HCC) is being diagnosed increasingly, and in one half of diagnosed patients, recurrence will develop. Thus, it is urgent to identify recurrence-related markers. We investigated the effectiveness of CpG methylation in predicting recurrence for patients with E-HCCs. Patients and Methods In total, 576 patients with E-HCC from four independent centers were sorted by three phases. In the discovery phase, 66 tumor samples were analyzed using the Illumina Methylation 450k Beadchip. Two algorithms, Least Absolute Shrinkage and Selector Operation and Support Vector Machine-Recursive Feature Elimination, were used to select significant CpGs. In the training phase, penalized Cox regression was used to further narrow CpGs into 140 samples. In the validation phase, candidate CpGs were validated using an internal cohort (n = 141) and two external cohorts (n = 191 and n =104). Results After combining the 46 CpGs selected by the Least Absolute Shrinkage and Selector Operation and the Support Vector Machine-Recursive Feature Elimination algorithms, three CpGs corresponding to SCAN domain containing 3, Src homology 3-domain growth factor receptor-bound 2-like interacting protein 1, and peptidase inhibitor 3 were highlighted as candidate predictors in the training phase. On the basis of the three CpGs, a methylation signature for E-HCC (MSEH) was developed to classify patients into high- and low-risk recurrence groups in the training cohort ( P < .001). The performance of MSEH was validated in the internal cohort ( P < .001) and in the two external cohorts ( P < .001; P = .002). Furthermore, a nomogram comprising MSEH, tumor differentiation, cirrhosis, hepatitis B virus surface antigen, and antivirus therapy was generated to predict the 5-year recurrence-free survival in the training cohort, and it performed well in the three validation cohorts (concordance index: 0.725, 0.697, and 0.693, respectively). Conclusion MSEH, a three-CpG-based signature, is useful in predicting recurrence for patients with E-HCC.
High Response Rate and Acceptable Toxicity of R-P-Imvp-16/CBDCA for Relapsed or Refractory Aggressive B-Cell Lymphoma
Authors: Takuro Matsumoto, Nobuhiko Nakamura, Yuhei Shibata, Hiroshi Nakamura, Ryoko Mabuchi, Junichi Kitagawa, Nobuhiro Kanemura, Naoe Goto, Senji Kasahara, Hideko Goto, Kenji Fukuno, Takeshi Hara, Toshiki Yamada, Michio Sawada, Takeshi Takahashi, Masami Oyama, Koshiro Saito, Hisashi Tsurumi
Journal: Blood (2014)
Phase I/II Study of Gemtuzumab Ozogamicin (GO), Fludarabine and Melphalan (FM) Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in AML/MDS.
Authors: M. de Lima, P. Thall, M. Shahjahan, W. Xuemei, D. Couriel, P. Anderlini, C. Hosing, M. Qazilbash, G. McCormick, C. Ippoliti, M. Donato, T. Martin, L. Metoyer, L. Griffin, P. Kebriaei, R. Champlin, S. Giralt
Journal: Blood (2004)
The Antileukemic Effect of NK and NK-T Cells Against Chronic Myelogenous Leukemia Is Dominated by Interactions between Activating Molecules and Their Ligands Which Overcome Inhibitory KIR-MHC Class I Interaction.
Authors: Giuseppe Sconocchia, Michelle Lau, Maurizio Provenzano, Katayoun Rezvani, Hiroshi Fujiwara, Soldano Ferrone, John Barrett
Journal: Blood (2004)